Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Belite Bio, Inc - American Depositary Shares (NQ:BLTE)

179.48 -3.53 (-1.93%)
Streaming Delayed Price Updated: 10:37 AM EST, Feb 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 44,900
Open 181.34
Bid (Size) 178.18 (100)
Ask (Size) 180.67 (200)
Prev. Close 183.01
Today's Range 176.38 - 182.88
52wk Range 49.00 - 200.00
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Belite Bio Announces Participation at the 41st Asia-Pacific Academy of Ophthalmology Congress (APAO)
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio Completes Enrollment in the DRAGON II Clinical Trial of Tinlarebant for Stargardt Disease (STGD1)
From Belite Bio, Inc
Via GlobeNewswire

Performance

YTD
+12.7%
+12.7%
1 Month
+16.0%
+16.0%
3 Month
+53.0%
+53.0%
6 Month
+158.2%
+158.2%
1 Year
+233.6%
+233.6%

More News

Read More
InvestorNewsBreaks – Belite Bio, Inc (NASDAQ: BLTE) Prices $350M Underwritten Public Offering of ADSs
Via Investor Brand Network
News headline image
Earnings Scheduled For November 10, 2025 ↗
Via Benzinga
News headline image
Earnings Outlook For Belite Bio ↗
Via Benzinga
News headline image
Belite Bio Announces Pricing of $350.0 Million Underwritten Public Offering of American Depositary Shares
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Why Belite Bio Stock Soared on Monday ↗
Via The Motley Fool
News headline image
Belite Bio Announces Proposed Underwritten Public Offering of American Depositary Shares
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Top movers in Monday's pre-market session ↗
Via Chartmill
News headline image
New Hope for People Living with a Disease Once Deemed Untreatable: Belite Bio Announces Positive Topline Results from the Pivotal Global, Phase 3 DRAGON Trial of Tinlarebant in Adolescents with Stargardt Disease
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Belite Bio to Host Webcast on November 10, 2025, to Discuss Third Quarter 2025 Financial Results
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio Announces UK’s Medicines and Healthcare Products Regulatory Agency Agrees to Conditional Marketing Authorization Application Based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant
From Belite Bio, Inc
Via GlobeNewswire
News headline image
CORRECTION -- International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 04, 2025
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 04, 2025
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Belite Bio to Present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference November 4th
From Virtual Investor Conferences; Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio to Participate in the Deutsche Bank ADR Virtual Investor Conference
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio to Participate in the 2025 Maxim Growth Summit
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio Announces China NMPA Agrees to New Drug Application with Priority Review based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant
From Belite Bio, Inc
Via GlobeNewswire
News headline image
3 Lesser-Known Healthcare Names With Major Upside in Store ↗
Via MarketBeat
News headline image
Belite Bio Announces Completion of DRAGON, a 2-Year, Phase 3 Trial of Oral Tinlarebant in the Treatment of Stargardt Disease
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio Announces Up to $275 Million Upsized Private Placement Financing by Leading Healthcare Investors
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio to Participate in Three Upcoming Investor Conferences
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
From Belite Bio, Inc
Via GlobeNewswire

Frequently Asked Questions

Is Belite Bio, Inc - American Depositary Shares publicly traded?
Yes, Belite Bio, Inc - American Depositary Shares is publicly traded.
What exchange does Belite Bio, Inc - American Depositary Shares trade on?
Belite Bio, Inc - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Belite Bio, Inc - American Depositary Shares?
The ticker symbol for Belite Bio, Inc - American Depositary Shares is BLTE on the Nasdaq Stock Market
What is the current price of Belite Bio, Inc - American Depositary Shares?
The current price of Belite Bio, Inc - American Depositary Shares is 179.48
When was Belite Bio, Inc - American Depositary Shares last traded?
The last trade of Belite Bio, Inc - American Depositary Shares was at 02/10/26 10:37 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.